ISCO
Price
$0.16
Change
-$0.00 (-0.00%)
Updated
Jun 26 closing price
Capitalization
1.26M
LIXT
Price
$0.71
Change
-$0.06 (-7.79%)
Updated
Jun 27 closing price
Capitalization
1.97M
Interact to see
Advertisement

ISCO vs LIXT

Header iconISCO vs LIXT Comparison
Open Charts ISCO vs LIXTBanner chart's image
International Stem Cell
Price$0.16
Change-$0.00 (-0.00%)
Volume$11.99K
Capitalization1.26M
Lixte Biotechnology Holdings
Price$0.71
Change-$0.06 (-7.79%)
Volume$23.09K
Capitalization1.97M
ISCO vs LIXT Comparison Chart in %
Loading...
LIXT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ISCO vs. LIXT commentary
Jun 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ISCO is a Hold and LIXT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 29, 2025
Stock price -- (ISCO: $0.16 vs. LIXT: $0.71)
Brand notoriety: ISCO and LIXT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ISCO: 205% vs. LIXT: 53%
Market capitalization -- ISCO: $1.26M vs. LIXT: $1.97M
ISCO [@Biotechnology] is valued at $1.26M. LIXT’s [@Biotechnology] market capitalization is $1.97M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ISCO’s FA Score shows that 1 FA rating(s) are green whileLIXT’s FA Score has 0 green FA rating(s).

  • ISCO’s FA Score: 1 green, 4 red.
  • LIXT’s FA Score: 0 green, 5 red.
According to our system of comparison, ISCO is a better buy in the long-term than LIXT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LIXT’s TA Score shows that 3 TA indicator(s) are bullish.

  • LIXT’s TA Score: 3 bullish, 6 bearish.

Price Growth

ISCO (@Biotechnology) experienced а +4.25% price change this week, while LIXT (@Biotechnology) price change was -14.18% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.22%. For the same industry, the average monthly price growth was +31.37%, and the average quarterly price growth was +12.88%.

Reported Earning Dates

ISCO is expected to report earnings on May 16, 2025.

LIXT is expected to report earnings on May 12, 2025.

Industries' Descriptions

@Biotechnology (+4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LIXT($1.97M) has a higher market cap than ISCO($1.26M). ISCO YTD gains are higher at: 92.989 vs. LIXT (-64.793). ISCO has higher annual earnings (EBITDA): 111K vs. LIXT (-3.31M). ISCO (1.45M) and LIXT (1.39M) have equal amount of cash in the bank . LIXT has less debt than ISCO: LIXT (100K) vs ISCO (4.1M). ISCO has higher revenues than LIXT: ISCO (9.09M) vs LIXT (0).
ISCOLIXTISCO / LIXT
Capitalization1.26M1.97M64%
EBITDA111K-3.31M-3%
Gain YTD92.989-64.793-144%
P/E RatioN/AN/A-
Revenue9.09M0-
Total Cash1.45M1.39M105%
Total Debt4.1M100K4,095%
FUNDAMENTALS RATINGS
ISCO vs LIXT: Fundamental Ratings
ISCO
LIXT
OUTLOOK RATING
1..100
5094
VALUATION
overvalued / fair valued / undervalued
1..100
5
Undervalued
68
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4097
P/E GROWTH RATING
1..100
90100
SEASONALITY SCORE
1..100
853

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ISCO's Valuation (5) in the null industry is somewhat better than the same rating for LIXT (68). This means that ISCO’s stock grew somewhat faster than LIXT’s over the last 12 months.

ISCO's Profit vs Risk Rating (100) in the null industry is in the same range as LIXT (100). This means that ISCO’s stock grew similarly to LIXT’s over the last 12 months.

ISCO's SMR Rating (100) in the null industry is in the same range as LIXT (100). This means that ISCO’s stock grew similarly to LIXT’s over the last 12 months.

ISCO's Price Growth Rating (40) in the null industry is somewhat better than the same rating for LIXT (97). This means that ISCO’s stock grew somewhat faster than LIXT’s over the last 12 months.

ISCO's P/E Growth Rating (90) in the null industry is in the same range as LIXT (100). This means that ISCO’s stock grew similarly to LIXT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LIXT
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
85%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
N/A
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
84%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
LIXT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WINT0.450.08
+21.49%
Windtree Therapeutics Inc.
OPEN0.560.02
+3.79%
Opendoor Technologies
PCTY179.562.40
+1.35%
Paylocity Holding Corp
NCMI4.89-0.01
-0.10%
National CineMedia
BATL1.41-0.09
-6.00%
Battalion Oil Corp

ISCO and

Correlation & Price change

A.I.dvisor tells us that ISCO and HNSBF have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ISCO and HNSBF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ISCO
1D Price
Change %
ISCO100%
N/A
HNSBF - ISCO
22%
Poorly correlated
N/A
CRDF - ISCO
20%
Poorly correlated
-0.32%
IGXT - ISCO
9%
Poorly correlated
N/A
LIXT - ISCO
7%
Poorly correlated
-7.19%
INTI - ISCO
7%
Poorly correlated
-2.09%
More

LIXT and

Correlation & Price change

A.I.dvisor tells us that LIXT and NTLA have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LIXT and NTLA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LIXT
1D Price
Change %
LIXT100%
-7.19%
NTLA - LIXT
28%
Poorly correlated
-0.52%
CAI - LIXT
28%
Poorly correlated
+0.22%
IBIO - LIXT
28%
Poorly correlated
+6.34%
BBIO - LIXT
27%
Poorly correlated
-0.58%
INCY - LIXT
27%
Poorly correlated
-3.45%
More